Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Iranzu Gonzalez-Borja"'
Autor:
Ibone Labiano, Ana E. Huerta, Maria Alsina, Hugo Arasanz, Natalia Castro, Saioa Mendaza, Arturo Lecumberri, Iranzu Gonzalez-Borja, David Guerrero-Setas, Ana Patiño-Garcia, Gorka Alkorta-Aranburu, Irene Hernández-Garcia, Virginia Arrazubi, Elena Mata, David Gomez, Antonio Viudez, Ruth Vera
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-12 (2024)
Abstract Pancreatic ductal adenocarcinoma represents one of the solid tumors showing the worst prognosis worldwide, with a high recurrence rate after adjuvant or neoadjuvant therapy. Circulating tumor DNA analysis raised as a promising non-invasive t
Externí odkaz:
https://doaj.org/article/f92620ce655e4f569495af68107a7fe1
Autor:
Emilia Alors‐Pérez, Ricardo Blázquez‐Encinas, María Trinidad Moreno‐Montilla, Víctor García‐Vioque, Juan Manuel Jiménez‐Vacas, Andrea Mafficini, Iranzu González‐Borja, Claudio Luchini, Juan M. Sánchez‐Hidalgo, Marina E. Sánchez‐Frías, Sergio Pedraza‐Arevalo, Antonio Romero‐Ruiz, Rita T. Lawlor, Antonio Viúdez, Manuel D. Gahete, Aldo Scarpa, Álvaro Arjona‐Sánchez, Raúl M. Luque, Alejandro Ibáñez‐Costa, Justo P. Castaño
Publikováno v:
Molecular Oncology, Vol 18, Iss 10, Pp 2524-2540 (2024)
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal cancer, characterized by late diagnosis and poor treatment response. Surgery is the only curative approach, only available to early‐diagnosed patients. Current therapies have limited effect
Externí odkaz:
https://doaj.org/article/de947d6fca6d49f9911a2528b10949ca
Autor:
Iranzu González-Borja, Emilia Alors-Pérez, Irene Amat, Laura Alonso, Cristina Viyuela-García, Saioa Goñi, José C. Reyes, María Ceballos-Chávez, Irene Hernández-García, Marina E. Sánchez-Frías, Enrique Santamaría, Socorro Razquin, Álvaro Arjona-Sánchez, Virginia Arrazubi, Jairo Pérez-Sanz, Ruth Vera, Joaquín Fernández-Irigoyen, Justo P. Castaño, Antonio Viúdez
Publikováno v:
Frontiers in Medicine, Vol 8 (2021)
Checkpoint with forkhead-associated and ring finger domains (CHFR) has been proposed as a predictive and prognosis biomarker for different tumor types, but its role in pancreatic ductal adenocarcinoma (PDAC) remains unknown. The aim of this study was
Externí odkaz:
https://doaj.org/article/aa8a20b687714e7c89f5590df6b0bb4f